Damle NK[au] - Search Results

Year	Number of Results
1979	3
1981	2
1982	2
1983	4
1984	4
1985	4
1986	3
1987	3
1988	2
1989	4
1990	3
1991	5
1992	6
1993	8
1994	1
1995	1
2002	1
2003	2
2004	4
2005	2
2006	4
2007	3
2008	3
2010	1
2011	1
2021	1
2022	0

1

ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.

Smith RA, Zammit DJ, Damle NK, Usansky H, Reddy SP, Lin JH, Mistry M, Rao NS, Denis LJ, Gupta S. Smith RA, et al. Among authors: damle nk. Mol Cancer Ther. 2021 Aug;20(8):1327-1337. doi: 10.1158/1535-7163.MCT-20-0565. Epub 2021 May 27. Mol Cancer Ther. 2021. PMID: 34045226

2

Antibody-targeted chemotherapy with immunoconjugates of calicheamicin.

Damle NK, Frost P. Damle NK, et al. Curr Opin Pharmacol. 2003 Aug;3(4):386-90. doi: 10.1016/s1471-4892(03)00083-3. Curr Opin Pharmacol. 2003. PMID: 12901947 Review.

3

Tumour-targeted chemotherapy with immunoconjugates of calicheamicin.

Damle NK. Damle NK. Expert Opin Biol Ther. 2004 Sep;4(9):1445-52. doi: 10.1517/14712598.4.9.1445. Expert Opin Biol Ther. 2004. PMID: 15335312 Review.

4

Biopharmaceutical drug discovery using novel protein scaffolds.

Gill DS, Damle NK. Gill DS, et al. Among authors: damle nk. Curr Opin Biotechnol. 2006 Dec;17(6):653-8. doi: 10.1016/j.copbio.2006.10.003. Epub 2006 Oct 19. Curr Opin Biotechnol. 2006. PMID: 17055245 Review.

5

Antigen-specific suppressor T lymphocytes in man.

Damle NK, Engleman EG. Damle NK, et al. Clin Immunol Immunopathol. 1989 Nov;53(2 Pt 2):S17-24. doi: 10.1016/0090-1229(89)90066-4. Clin Immunol Immunopathol. 1989. PMID: 2551552 Review.

6

Interleukin 2-activated killer lymphocytes in man.

Damle NK, Bradley EC. Damle NK, et al. Year Immunol. 1988;3:138-43. Year Immunol. 1988. PMID: 3327308 Review. No abstract available.

7

Immunoregulatory T lymphocytes in man. Cell surface molecules involved in their function.

Damle NK, Engleman EG. Damle NK, et al. Year Immunol. 1985:39-50. Year Immunol. 1985. PMID: 2953144 Review. No abstract available.

8

Antibody-drug conjugates ace the tolerability test.

Damle NK. Damle NK. Nat Biotechnol. 2008 Aug;26(8):884-5. doi: 10.1038/nbt0808-884. Nat Biotechnol. 2008. PMID: 18688241 No abstract available.

9

CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.

Dijoseph JF, Dougher MM, Armellino DC, Kalyandrug L, Kunz A, Boghaert ER, Hamann PR, Damle NK. Dijoseph JF, et al. Among authors: damle nk. Cancer Immunol Immunother. 2007 Jul;56(7):1107-17. doi: 10.1007/s00262-006-0260-5. Epub 2006 Dec 12. Cancer Immunol Immunother. 2007. PMID: 17160682

10

Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy.

Boghaert ER, Khandke K, Sridharan L, Armellino D, Dougher M, Dijoseph JF, Kunz A, Hamann PR, Sridharan A, Jones S, Discafani C, Damle NK. Boghaert ER, et al. Among authors: damle nk. Int J Oncol. 2006 Mar;28(3):675-84. Int J Oncol. 2006. PMID: 16465373

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results